Company Overview
Snapshot
Founded in January 2021 by Dr. Ettie Maman, Rohi Hourvitz, Prof. Ariel Hourvitz, and Dr. Micha Baum, FertilAI operates with 11–50 employees. The company has secured funding across two rounds from three investors, including lead investors Redseed and Longevity Venture Partners. In April 2026, FertilAI received CE marking under the EU Medical Device Regulation for its AI-driven clinical decision support tools.
Business overview
FertilAI develops AI algorithms to enhance the success rates of fertility treatments by improving the complex workflows between doctors and patients. The company's core technology focuses on predictive AI for natural cycle ovulation and clinical decision support tools. FertilAI serves the healthcare market, specifically clinics, hospitals, and gynecology practices, operating within the digital healthcare, medical decision support, and femtech sectors.
Strategic signal
In April 2026, FertilAI secured the world's first CE mark for predictive AI in fertility treatment cycle optimization. This regulatory approval under the EU Medical Device Regulation validates the company's AI-driven clinical decision support tools, signaling a significant step towards market entry and broader adoption in the European healthcare landscape. For investors, this demonstrates a critical de-risking event and potential for commercial scale.
Log in to access full profile ›Company Intelligence Q&A
- When was FertilAI founded?
- FertilAI was founded in January 2021 by Dr. Ettie Maman, Rohi Hourvitz, Prof. Ariel Hourvitz, and Dr. Micha Baum.
- What significant regulatory approval did FertilAI receive?
- In April 2026, FertilAI received CE marking under the EU Medical Device Regulation (EU MDR) for its AI-driven clinical decision support tools, which are designed to optimize fertility treatment cycles.
- What was FertilAI's most recent funding round?
- In November 2024, FertilAI raised $4.5M in a Seed funding round. The round was led by Redseed and Longevity Venture Partners.
- What is FertilAI's primary focus?
- FertilAI focuses on developing AI algorithms to increase the success rates of fertility treatments, with an emphasis on improving workflows between doctors and patients.
- Has FertilAI received any grants?
- In January 2021, FertilAI secured a grant from the Israel Innovation Authority to develop a first pilot site.